Differential systemic gene expression profile in patients with diabetic macular edema: Responders versus nonresponders to standard treatment

Indian Journal of Ophthalmology

Volumn 62, Issue 1, 2014, Pages 66-73

  Dabir, Supriya S ^a   Das, Debashish ^a   Nallathambi, Jeyabalan ^a   Mangalesh, Shwetha ^a   Yadav, Naresh K ^a   Schouten, Jan S A G ^b  

^a Narayana Health City   (India)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bevacizumab; diabetic macular edema; gene expression profile; microarray analysis

Indexed keywords

ANGIOGENESIS INHIBITOR; RNA;

CASE CONTROL STUDY; CONFERENCE PAPER; DIABETIC RETINOPATHY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LASER COAGULATION; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RETINA MACULA EDEMA; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; CASE-CONTROL STUDIES; DIABETIC RETINOPATHY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84893549067     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.126186     Document Type: Conference Paper

References (30)

1. El-Shazly SF, El-Bradey MH, Tameesh MK. Vascular endothelial growth factor gene polymorphism prevalence inpatients with diabetic macular edema and its correlation with anti-VEGF treatment outcomes. Clin Experiment Ophthalmol 2013 [In Press].
2. Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N. Current treatments in diabetic macular oedema: Systematic review and meta-analysis. BMJ Open 2013;3:e002269.
3. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: Pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
4. Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, et al. Burden of illness of diabetic macular edema: Literature review. Curr Med Res Opin 2010;26:1587-97.
5. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-15.
6. American Academy of Ophthalmology. Preferred Practice Pattern: Diabetic Retinopathy. http://one.aao.org/CE/PracticeGuidelines/PPP.aspx [Last Accessed on 2011 July 20].
7. Pietrzyk JJ, Kwinta P, Bik-Multanowski M, Madetko-Talowska A, Jaga M, Tomasik T, et al. New insight into the pathogenesis of retinopathy of prematurity: Assessment of whole-genome expression. Pediatr Res 2013;73:476-83.
8. Parrish ML, Wright C, Rivers Y, Argilla D, Collins H, Leeson B, et al. cDNA targets improve whole blood gene expression profiling and enhance detection of pharmocodynamic biomarkers: A quantitative platform analysis. J Transl Med 2010;8:87.
9. Jin M, Kashiwagi K, Iizuka Y, Tanaka Y, Imai M, Tsukahara S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 2001;21:28-33.
10. Yildirim N, Sahin A, Erol N, Kara S, Uslu S, Topbas S. The relationship between plasma MMP-9 and TIMP-2 levels and intraocular pressure elevation in diabetic patients after intravitreal triamcinolone injection. J Glaucoma 2008;17:253-6.
11. Mohammad G, Kowluru RA. The role of Raf-1 kinase in diabetic retinopathy. Expert Opin Ther Targets 2011;15:357-64.
12. Kirwin SJ, Kanaly ST, Hansen CR, Cairns BJ, Ren M, Edelman JL. Retinal gene expression and visually evoked behavior in diabetic long evans rats. Invest Ophthalmol Vis Sci 2011;52:7654-63.
13. Yoshida S, Shimmura S, Nagoshi N, Fukuda K, Matsuzaki Y, Okano H, et al. Isolation of multipotent neural crest-derived stem cells from the adult mouse cornea. Stem Cells 2006;24:2714-22.
14. Lee K, Hu Y, Ding L, Chen Y, Takahashi Y, Mott R, et al. Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy. Diabetes 2012;61:2948-57.
15. Speicher MA, Danis RP, Criswell M, Pratt L. Pharmacologic therapy for diabetic retinopathy. Expert Opin Emerg Drugs 2003;8:239-50.
16. Khatami M. Regulation of MI transport in retinal pigment epithelium by sugars, amiloride, and pH gradients: Potential impairment of pump-leak balance in diabetic maculopathy. Membr Biochem 1990;9:279-92.
17. Costa PZ, Soares R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci 2013;92:1037-45.
18. Praidou A, Androudi S, Brazitikos P, Karakiulakis G, Papakonstantinou E, Dimitrakos S. Angiogenic growth factors and their inhibitors in diabetic retinopathy. Curr Diabetes Rev 2010;6:304-12.
19. Le Goff MM, Lu H, Ugarte M, Henry S, Takanosu M, Mayne R, et al. The vitreous glycoprotein opticin inhibits preretinal neovascularization. Invest Ophthalmol Vis Sci 2012;53:228-34.
20. Simunovic F, Steiner D, Pfeifer D, Stark GB, Finkenzeller G, Lampert F. Increased extracellular matrix and proangiogenic factor transcription in endothelial cells after cocultivation with primary human osteoblasts. J Cell Biochem 2013;114:1584-94.
21. Lan HY, Chung AC. Transforming growth factor-beta and Smads. Contrib Nephrol 2011;170:75-82.
22. Kloeckener-Gruissem B, Barthelmes D, Labs S, Schindler C, Kurz-Levin M, Michels S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011;52:4694-702.
23. Knudsen ST. Ambulatory blood pressure, endothelial perturbation, and microvascular complications in type 2 diabetes. Dan Med Bull 2010;57:B4145.
24. Meleth AD, Agrón E, Chan CC, Reed GF, Arora K, Byrnes G, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005;46:4295-301.
25. Lee WJ, Kang MH, Seong M, Cho HY. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol 2012;96:1426-30.
26. Jonas JB, Jonas RA, Neumaier M, Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina 2012;32:2150-7.
27. Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: Novel therapeutic targets. Middle East Afr J Ophthalmol 2012;19:52-9.
28. Koskela UE, Kuusisto SM, Nissinen AE, Savolainen MJ, Liinamaa MJ. High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy. Ophthalmic Res 2013;49:108-14.
29. Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009;4:e8158.
30. Tremolada G, Lattanzio R, Mazzolari G, Zerbini G. The therapeutic potential of VEGF inhibition in diabetic microvascular complications. Am J Cardiovasc Drugs 2007;7:393-8.